Would you use tucatinib in a patient with recurrent HER2+ breast cancer with isolated brain metastasis with leptomeningeal disease?
Patient received adjuvant chemotherapy and anti-Her2 therapy 3 years ago.
Answer from: Medical Oncologist at Academic Institution
I certainly would, given the CNS activity seen in the HER2CLIMB trial. I would follow the same paradigm and combine it with capecitabine and trastuzumab.
Sign in or Register to read more